Methicillin-resistant Staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy

Bucheit, John D.; Collins, Rebeccah J.; Joshi, Prajwol

doi:10.2146/ajhp130246

Cited by 13 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An additional single case report describes the use of ceftaroline to treat MRSA bacteremia and an epidural abscess [17]. The patient was initially treated with 4 days of vancomycin, 7 days of daptomycin, and surgical debridement but continued to do poorly.…”

Section: Resultsmentioning

confidence: 99%

Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review

Cosimi

Beik

Kubiak³

et al. 2017

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Ceftaroline is approved by the Food and Drug Administration for acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia, including cases with concurrent bacteremia. Use for serious methicillin-resistant Staphylococcus aureus (MRSA) infections has risen for a multitude of reasons. The aim of this article is to review the literature evaluating clinical outcomes and safety of ceftaroline prescribed for serious MRSA infections. We conducted a literature search in Ovid (Medline) and PubMed for reputable case reports, clinical trials, and reviews focusing on the use of ceftaroline for treatment of MRSA infections. Twenty-two manuscripts published between 2010 and 2016 met inclusion criteria. Mean clinical cure was 74% across 379 patients treated with ceftaroline for severe MRSA infections. Toxicities were infrequent. Ceftaroline treatment resulted in clinical and microbiologic cure for severe MRSA infections. Close monitoring of hematological parameters is necessary with prolonged courses of ceftaroline.

show abstract

Section: Resultsmentioning

confidence: 99%

Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review

Cosimi

Beik

Kubiak³

et al. 2017

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…1 This medication has also been reported to be used for the sporadic treatment of other severe MRSA infections, including osteomyelitis 2 and epidural abscesses. 3 A middle-aged man with diabetes mellitus was admitted for incision and drainage of a septic left wrist. Source control was achieved.…”

mentioning

confidence: 99%

In vivoemergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis: Table 1.

Sanchez

Mendes

Sader

et al. 2016

J. Antimicrob. Chemother.

View full text Add to dashboard Cite

cluster was typed by MLST according to the Pasteur Institute scheme (www.pasteur.fr/mlst), giving rise to the subsequent clones ST326 (CX1), ST405 (CX2), ST147 (CX3), ST104 (CX4 and CX5) and ST15 (CX6) (Figure 1). Of note, all clones except ST104 had previously been associated with OXA-48 production in Europe and/or Spain. 1,8,9 The concomitant occurrence of five different K. pneumoniae clones producing OXA-48 in a single hospital might be explained, at least in part, by the high transfer frequency of the IncL/M plasmid carrying the bla OXA-48 gene. 10 In view of our data, it is likely that the spread of OXA-48-producing K. pneumoniae in Spain will rapidly mirror the endemic situation observed in Italy and the USA with KPC-producing K. pneumoniae isolates. Once again, this bacterial species is playing a pivotal role in the emergence and dispersion of resistance traits in hospital settings. Urgent hygiene measures have to be taken to prevent further consolidation of a difficult-to-control situation.

show abstract

“…One recent large multicentre retrospective study included 527 patients and most (67%) were treated for off-label infections [12], a lower rate than in our series in which this group of patients represented 85.7% of the cases. Notably, these included 5 CNS infections (6%) and 19 osteoarticular infections (22.6%), in which previous experience is even more scarce [9][10][11]13].…”

Section: Discussionmentioning

confidence: 99%

“…Clinical data on the effectivity of ceftaroline in off-label indications in scarce and rests upon case series, fundamentally used as salvage therapy [ 5 – 11 ]. One recent large multicentre retrospective study included 527 patients and most (67%) were treated for off-label infections [ 12 ], a lower rate than in our series in which this group of patients represented 85.7% of the cases.…”

Section: Discussionmentioning

confidence: 99%

Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital

Álvarez¹,

Merino²,

Corral³

et al. 2021

Rev Esp Quimioter

View full text Add to dashboard Cite

Objective. To determine the indications, success rate and adverse effects of ceftaroline fosamil treatment in a tertiary hospital. Material and methods. In total, 84 cases from February 2018 to December 2019 were retrospectively analysed. No exclusion criteria were applied. Results. Eighty-four patients, with a median age of 70 years, of which, 6.7% (56) were male, were treated with ceftaroline fosamil for a median of 14 days. Most indications were off-label, including 29 endocarditis (34.5%), 14 bacteraemia (16.6%), 5 Central nervous system (CNS) infections (6%) and 19 osteoarticular infections (22.6%). Staphylococcus aureus was the most frequently isolated microorganism, including 28 methicillin-sensitive S. aureus (MSSA; 33.3%) and 14 methicillin-resistant S. aureus (MRSA; 16.7%), followed by coagulase-negative Staphylococcus (23, 27.4%). The main reason for ceftaroline fosamil prescription was the failure of previous treatment (41.7% of cases). Treatment was successful in 60/84 patients (71.4%) and failed clinically or microbiologically in 14 (16.7%). Eight patients died for a reason not related to the infection and two were found to have a non-infectious condition. Twenty-two of thirty-five (62.8%) patients prescribed ceftaroline because of failure of previous treatment improved, including eight endocarditis and seven bacteraemia. Adverse effects were reported in five patients (5.9%) including neutropenia, thrombocytopenia, transaminases elevation and creatinine elevation; all except one were mild and all resolved after discontinuation of treatment. Conclusions. Ceftaroline fosamil is a well-tolerated cephalosporine, effective against multi- resistant gram-positive and many gram-negative microorganisms. Our experience suggests that it is effective as a rescue or first-line therapy in other indications than those currently approved.

show abstract

Methicillin-resistant Staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy

Abstract: A MRSA epidural abscess in a 48-year-old woman was successfully treated with ceftaroline fosamil 600 mg every 12 hours as salvage therapy.

Cited by 13 publications

References 17 publications

Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review

Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review

In vivoemergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis: Table 1.

Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital

Contact Info

Product

Resources

About